Loading
AG
Ashland Global Holdings Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 May 2022.
Ashland Global Holdings Inc: what insiders have been doing
Ashland Global Holdings Inc belongs to the Chemicals & Materials sector. Filings by its managers are published through SEC (Form 4). No insider at Ashland Global Holdings Inc has published a filing in the past twelve months. The most recent one dates from 9 June 2022.
Looking back to 2021, when coverage begins, insiders filed 1 purchase and 1 sale.
Other companies in the same sector with recent insider buying flagged by our signals: Culp Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
29
Thresholds
n/a
Buy Volume
€5M
1 ops. · all time
Sell Volume
€88,033
1 ops. · all time
Since the insiders bought
- -14.9%Entry 101.76 · Close at T+365 86.63
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 9 June 2022
Declarations29 total
5,838 shares@ US$37.3731.5% of flowCommon StockSEC:0001127602-22-017121:0
4,940 shares@ US$46.6529.6% of flowCommon StockSEC:0001127602-22-016626:0
48,800 shares@ US$101.27100.0% of flowCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-22-003033:0
Canonical exit: 15 Aug 2022 (T+90)
2,000 shares@ US$67.1666.0% of flowCommon StockSEC:0001127602-22-012087:0
4,686 shares@ US$94.4359.2% of flowCommon StockSEC:0001127602-22-010159:0
269.391 sharesCommon StockSEC:0001127602-22-003300:0
469 shares0Common StockSEC:0001127602-22-000460:0
26 shares@ US$104.010.1% of flowCommon StockSEC:0001127602-21-031632:0
8,996 shares@ US$104.0141.2% of flowCommon StockSEC:0001127602-21-031072:0
1,130 shares@ US$37.37100.0% of flowCommon StockSEC:0001127602-21-030222:0
7,858 shares@ US$106.9336.8% of flowCommon StockSEC:0001127602-21-029727:0
319 shares@ US$106.934.7% of flowCommon StockSEC:0001127602-21-029719:0
571 shares@ US$106.9328.7% of flowCommon StockSEC:0001127602-21-029729:0
571 shares@ US$106.9374.3% of flowCommon StockSEC:0001127602-21-029722:0
2,524 shares@ US$106.9332.6% of flowCommon StockSEC:0001127602-21-029728:0
621.995 shares@ US$106.93100.0% of flowCommon StockSEC:0001127602-21-029730:0
1,396 shares@ US$106.9319.5% of flowCommon StockSEC:0001127602-21-029726:0
4,675 shares@ US$108.1721.9% of flowCommon StockSEC:0001127602-21-029467:0
841 shares@ US$108.1711.8% of flowCommon StockSEC:0001127602-21-029465:0
105 shares@ US$108.175.3% of flowCommon StockSEC:0001127602-21-029476:0
1,393 shares@ US$108.1718.0% of flowCommon StockSEC:0001127602-21-029471:0
172 shares@ US$108.172.5% of flowCommon StockSEC:0001127602-21-029463:0
2,000 shares@ US$37.379.5% of flowCommon StockSEC:0001127602-21-026689:0
25 of 29 declarations
About Ashland Global Holdings Inc
Ashland Global Holdings Inc. (NYSE: ASH) is a U.S.-listed company trading on the NYSE in the United States, focused on specialty additives and ingredients. Headquartered in Wilmington, Delaware, Ashland has a long industrial heritage dating back more than a century and has gradually transformed its portfolio into a more focused, higher-value business centered on performance ingredients and formulation science. The company primarily serves end markets in life sciences, personal care, and architectural coatings, where technical differentiation, product quality, and customer support matter more than commodity pricing. ([investor.ashland.com](https://investor.ashland.com/corporate-profile?utm_source=openai))
Today, Ashland operates as a global supplier of functional additives and specialty ingredients. Its business covers pharmaceutical excipients and enabling materials, personal care ingredients, and additives used in coatings and other industrial formulations. In personal care, the company emphasizes biofunctional actives and ingredients for skin, hair, oral care, microbial protection, and home care. In specialty additives, Ashland offers technologies designed to improve thickening efficiency, leveling, sag resistance, substrate wetting, slip, and overall formulation performance. Safety, regulatory compliance, and product quality are recurring themes in the company’s positioning because they are essential in the highly regulated markets it serves. ([investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-announces-strategic-partnership-imcd-exclusive?utm_source=openai))
Read moreShow less
From a competitive standpoint, Ashland is best viewed as a niche specialty chemicals player with strong technical know-how rather than a bulk materials company. Its edge comes from application expertise, proprietary platforms, close relationships with formulators, and a global go-to-market model. Management continues to describe Ashland as a leader in high-quality, consumer-oriented markets such as pharmaceuticals, personal care, and architectural coatings. That positioning gives the company attractive pricing power in selected areas, although it also leaves it exposed to softer demand in certain coatings, construction, and industrial channels when macro conditions weaken. ([investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-reports-first-quarter-fiscal-2026-results-and-narrows?utm_source=openai))
Geographically, Ashland serves customers worldwide through a global footprint of commercial, technical, and manufacturing capabilities. Recent updates also show a clear portfolio-optimization agenda. The company has been pruning non-core or lower-margin activities, while reinvesting in innovation-led growth platforms. In 2025 and 2026, Ashland launched collapeptyl™, a new biofunctional for collagen-related skincare applications, completed the sale of its Avoca business, and announced an exclusive U.S. distribution partnership with IMCD for its personal care and home care ingredients. These actions underline a strategy focused on simplification, improved mix, and stronger customer reach. ([investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-unveils-collapeptyltm-revolutionary-biofunctional?utm_source=openai))
For investors, Ashland stands out as a specialty chemicals company with a long operating history, a refined portfolio, and exposure to attractive end markets. Its recent corporate actions suggest a continued emphasis on innovation, cost discipline, and margin improvement, while its listed status on the NYSE in the United States makes it relevant for both U.S. and international equity investors tracking specialty materials names. ([investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-reports-first-quarter-fiscal-2026-results-and-narrows?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
